oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Search Results: 1 - 10 of 94 matches for " Rifampicin "
All listed articles are free for downloading (OA Articles)
Page 1 /94
Display every page Item
Molecular characterization of the rpoB gene mutations of Mycobacterium tuberculosis isolated from China  [PDF]
Shengfen Wang, Bing Zhao, Yuanyuan Song, Yang Zhou, Yu Pang, Xichao Ou, Qiang Li, Yanlin Zhao, Hui Xia
Journal of Tuberculosis Research (JTR) , 2013, DOI: 10.4236/jtr.2013.11001
Abstract: Objective: To analyze characterization of the rpoBgene mutations of Mycobacterium tuber- culosis isolated from China and to explore the association of specific mutations conferring rifampicin (RIF) resistance with Beijing genotype strains. Methods: Genotypic analysis of 3479M. tuberculosis isolatesincluding 402 RIF-resistantand 3077 RIF-susceptible isolated from the na- tional drug-resistant tuberculosis baseline survey was performed. Results: DNA sequencing analysis of the 81-bp RIF resistance determining region (RRDR) of the ropB
gene revealed that 98.01% of RIF-resistant strains showedrpoBgene mutation, isolates with mutations at codon rpoB531, rpoB 526 and rpoB 516 were the most frequently. Analysis of the rpoB gene of 3077 RIF-susceptible strains revealed that 98.96% of the strains had no
mutation. The distribution of mutation frequency at differentcritical codons in different regions of China was statistically significant (p = 0.001). There was no significant difference in the occurrence of mutations at critical codons between the rifampicin-resistant Bei-jing and non-Beijing isolates.Conclusion: About 98% of RIF-resistant strains isolated from China carry mutations in RRDR ofrpoB gene.Mutation profiles in RIF-resistantM. tuberculosis clinical isolates are variable depending on the different geographical regionsof China. The results provide valuable information in adopting new molecular methods for diagnosis of TB in China.


Rapid Molecular Detection of Tuberculosis and Rifampicine Resistance in Ecuador  [PDF]
Fabián Pardón, Saddy Andrade, Lilian Campa?á, Homero Jinéz, José P. Barberán, Yolanda Valdés, Alexandra Narváez, Nancy V. Cajas
Advances in Infectious Diseases (AID) , 2017, DOI: 10.4236/aid.2017.74013
Abstract: Background: In Ecuador, tuberculosis (TB) remains a serious problem that is complicated by the emergence of multidrug-resistant TB (MDR-TB). To evaluate this problem, this study was carried out at the Social Security Hospital (IESS) in Guayaquil, Ecuador from 2013 to 2015. Methods: The Xpert TB/RIF system was used to detect TB and MDR-TB and a survey was carried out to identify the factors that are potentially causing MDR-TB. Findings: 200 TB patients were confirmed on 5649 suspected patients and 20 (10%) with MDR-TB. It was observed that the annual prevalence of TB and MDR-TB had declining during study period. Trends have been declining but co-infection has doubled since 2009 with 16% of patients co-infected with HIV. Potential resistance factors identified were: disruption in drug supply, lack of resources and lack of credibility of treatment.
Poor response to tuberculosis treatment with regimens without rifampicin in immunosuppressed AIDS patients
O'Donnel, M.M.;Souza Carvalho, S.;Gadelha, A.J.;Morgado, M.G.;Galhardo, M.C.G.;Louren?o, M.C.;Rolla, V.C.;
Brazilian Journal of Infectious Diseases , 2002, DOI: 10.1590/S1413-86702002000600001
Abstract: a prospective study was conducted on 79 advanced immunosuppressed aids patients from 1997 to 1999, during which nine cases of tuberculosis (tb) were diagnosed. the main clinical and laboratory characteristics and the response to tb treatment were reviewed. the clinical manifestations of tb were: pulmonary (six cases), extrapulmonary (two cases) and disseminated (one case). these patients were being treated with highly active antiretroviral treatment (haart) and were not responding. in three cases an optional regimen without rifampicin (rmp) was indicated to maintain haart during tb treatment. a clinical response to tb treatment (disappearance of fever) was observed in 6/9 patients during a mean of 73 days (sd = 96). the three unresponsive patients were those treated without rmp. a switch to tb regimens containing rmp was proposed and successful. in our study, though it was limited by a small sample size, the response to tb regimens without rifampin was poor in immunossupressed patients failing haart.
Rifampicin-induced acute thrombocytopenia
Banu Rekha V,Adhilakshmi A,Jawahar M
Lung India , 2005,
Abstract: Rifampicin is an essential component of the treatment regimen for tuberculosis. Extensive clinical experience has shown that the drug is well tolerated, but on rare occasions it can cause life threatening adverse reactions like acute renal failure and thrombocytopenia. At the Tuberculosis Research Centre, we have treated more than 8000 patients with pulmonary and extra-pulmonary tuberculosis with rifampicin-containing regimens over the past 30 years and we are reporting a case of acute thrombocytopenia probably rifampicin induced, in a patient who was retreated for tuberculosis. The physician treating tuberculosis patients must be aware of this rare life threatening complication, which if detected early, is completely reversible.
HEPATOTOXICITY OF ATT
GHULAM ABBAS KHAN NIAZI,ABDUL REHMAN ARSHAD,MANZAR ZAKARIA
The Professional Medical Journal , 2010,
Abstract: Objectives: To determine the frequency of hepatotoxicity with standard ATT. Study design: Descriptive. Setting: Department of Medicine, Combined Military Hospital Lahore. Period: Feb 2007 to April 2008. Materials & methods: 250 patients aged 18 years or greater having pulmonary TB were selected through non-probability convenience sampling technique. All patients were given four drugs for two monthsindoors, followed by two drugs for four months in outdoor. Symptoms suggestive of hepatotoxicity were enquired from the patients regularly. Serum bilirubin and ALT were measured on monthly basis and finally on completion of therapy. Hepatotoxicity was defined as a five fold rise in serum ALT. In patients developing hepatotoxicity, treatment was modified accordingly. Results: This study was done on 189 male and 61 female patients (total: 250). Hepatotoxicity developed in 13 (5.2%) patients, mostly during the initial phase of treatment (84.6% incidence during the first month). Risk factors included: age (4 out of 156 young patients and 9 out of 94 older patients; p: 0.016) and nutritional status (8 malnourished patients and 5 well nourished patients; p: 0.031). Hepatotoxicity was not related to the gender (9 males and 4 females; p: 0.585) or the results of baseline sputum smears (7 out of 102 smear positive cases and six out of 148 smear negative cases; p: 0.064). Conclusions: Hepatotoxicity with ATT is fairly common, especially in the elderly, malnourished patients and during the initial phase of treatment.
Rifampicin and dapsone in superficial pustular folliculitis
Prasad P
Indian Journal of Dermatology, Venereology and Leprology , 1996,
Abstract: Fifty male patients diagnosed to have superficial pustular folliculitis (SPF) were included in an open trial to study the effects of rifampicin vs dapsone. Rifampicin, in a dose of 10mg/kg body weight for a period of 8 weeks was given for 25 patients in phase I and the drug cleared the lesions in 72%. Dapsone in a dose of 100 mg/day produced moderate response in 20% only. 17 patients who did not clear with dapsone were started on rifampicin (phase II) and 7/17 showed marked improvement. Remissions with rifampicin ranged from 3-9 months or longer. In patients who relapsed, a second course of the drug was effective.
Rifampicin-induced thrombocytopenia
Verma Ajay,Singh Arpita,Chandra Amol,Kumar Santosh
Indian Journal of Pharmacology , 2010,
Abstract: In the treatment of tuberculosis there are special therapeutic problems related to adverse effects of drugs, compliance to treatment, and microbial resistance. Thrombocytopenia is an uncommon but potentially fatal adverse effect of certain anti-tubercular drugs when the incriminating drug is taken by a susceptible individual. We report a case of rifampicin-induced thrombocytopenia, which although rare, needs attention.
Oral rifampicin in cases of cutaneous leishmaniasis with multiple lesions (A pilot study)
Bumb R,Mehta R
Indian Journal of Dermatology, Venereology and Leprology , 2002,
Abstract: The multiple lesions of cutaneous leishmaniasis (CL) require an effective oral agent. We are reporting a pilot study of oral rifampicin 600 mg. bid or 20 mg/kg. body weight in cases of CL with multiple lesions. Our study shows 83.3% parasitological and clinical cure with insignificant side effects after 4 weeks of therapy. No relapse upto 6 months of completion of study was seen.
Pharmiacockinetic Interaction Between Naproxen and Rifampicin
Muhammad Tayyab Ansari,Bashir Ahmed Loothar,Qasim Jahangir Khan
Journal of Medical Sciences , 2003,
Abstract: Rifampicin and Naproxen are commonly co-administered to patients suffering from tuberculosis as well as osteoarthritis, so the effect of naproxen (500 mg) on the pharmacokinetics of rifampicin (450 mg) was evaluated in healthy human subject (n=10). Subjects participated in a two way crossover trial, the first dosing condition was rifampicin alone (control) and the second dosing condition was naproxen with rifampicin. The concentrations of rifampicin from the serum samples were determined by HPLC. The pharmacokinetic parameters indicated a significant (P<0.05) increase in elimination rate constant (Ke), clearance (Cl), volume of distribution (Vd), while significant decrease in the mean residence time (MRT) and area under the concentration-time curve (AUC) when rifampicin given with naproxen. Non-significant increase and decrease in absorption rate constant (Ka) and elimination half life (t1/2), time for maximum concentration (Tmax), maximum drug concentration (Cmax), respectively was observed. It may be concluded that these drugs may not be administered concomitantly due to their kinetic interactions.
Poor response to tuberculosis treatment with regimens without rifampicin in immunosuppressed AIDS patients
O'Donnel M.M.,Souza Carvalho S.,Gadelha A.J.,Morgado M.G.
Brazilian Journal of Infectious Diseases , 2002,
Abstract: A prospective study was conducted on 79 advanced immunosuppressed AIDS patients from 1997 to 1999, during which nine cases of tuberculosis (TB) were diagnosed. The main clinical and laboratory characteristics and the response to TB treatment were reviewed. The clinical manifestations of TB were: pulmonary (six cases), extrapulmonary (two cases) and disseminated (one case). These patients were being treated with highly active antiretroviral treatment (HAART) and were not responding. In three cases an optional regimen without rifampicin (RMP) was indicated to maintain HAART during TB treatment. A clinical response to TB treatment (disappearance of fever) was observed in 6/9 patients during a mean of 73 days (SD = 96). The three unresponsive patients were those treated without RMP. A switch to TB regimens containing RMP was proposed and successful. In our study, though it was limited by a small sample size, the response to TB regimens without rifampin was poor in immunossupressed patients failing HAART.
Page 1 /94
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.